Frequency Electronics (NasdaqGM:FEIM) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsThomas McClelland - President and CEOWiliam Bremer - Founder and Chief Investment OfficerBrett Reiss - Senior VPSteve Bernstein - CFOConference Call ParticipantsNone - Analyst 2George Marema - Research AnalystNone - Analyst 1Jeff Van Rhee - Partner and Equity Research AnalystOperatorGreetings, and welcome to the Frequency Electronics Second Quarter Fiscal 2026 Earnings Release Conference Call. At th ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsStephanie Piazzola - VP of Equity Research Medical TechnologyVaseem Mahboob - CFOBrian Webster - President and CEODavid Roman - Managing DirectorNeil Bhalodkar - VP of Investor RelationsNone - Company RepresentativeConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMichae ...

Kestra Medical Technologies (NasdaqGS:KMTS) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsStephanie Piazzola - VP of Equity Research Medical TechnologyVaseem Mahboob - CFOBrian Webster - President and CEODavid Roman - Managing DirectorNeil Bhalodkar - VP of Investor RelationsNone - Company RepresentativeConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMichae ...

Financial Data and Key Metrics Changes - The company reported revenue of $17.1 million for Q2 fiscal 2026, representing a 24% sequential increase and the third highest quarterly revenue in the past decade [3][11] - Consolidated net income for the quarter was approximately $1.8 million, or $0.18 per share, compared to approximately $2.7 million, or $0.28 per share for the same period of the previous fiscal year [15] - The fully funded backlog at the end of October 2025 was approximately $82 million, up from approximately $70 million at the previous fiscal year-end [16] Business Line Data and Key Metrics Changes - Revenue from commercial and U.S. government satellite programs was approximately $4.6 million, down from $9.4 million in the same period of the prior fiscal year [11] - Revenue from non-space U.S. government and Department of Defense customers was $11.9 million, accounting for approximately 69% of consolidated revenue, compared to 37% in the prior fiscal year [11] - Other commercial industrial revenues were approximately $560,000, slightly down from approximately $591,000 in the prior fiscal year [12] Market Data and Key Metrics Changes - The company anticipates significant growth in non-space defense products, which contributed to the increase in backlog [45] - The company expects a reversal in backlog growth towards space-related contracts in the upcoming quarters [46] Company Strategy and Development Direction - The company is focusing on growth opportunities in quantum sensing, proliferated satellites, and alternative position navigation and timing (ALT-PNT) programs, which are expected to be additive to the current business [5][6] - The company has established a facility in Colorado focused on quantum technology and low-phase noise oscillator technology, aiming to attract talent from local research institutions [22][23] - The company maintains strong strategic partnerships with major prime contractors, enhancing its competitive position in the defense sector [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing a strong core business and new market opportunities [9] - The company believes that defense spending will remain robust regardless of political changes, driven by global security concerns [68][69] - Management indicated that many delays in revenue recognition were due to customer-driven issues rather than the government shutdown, and they expect to see normalization of margins in the near term [30][39] Other Important Information - The company is debt-free and has a strong working capital position of approximately $31 million, with a current ratio of approximately 2.6 to 1 [16] - The company plans to continue investing in R&D to maintain its technological edge [14] Q&A Session Summary Question: Can you provide details on the Golden Dome Awards? - Management indicated that they anticipate participating in various aspects of the Golden Dome initiative, particularly in ground-based and space-based missile defense [20][21] Question: What activities are ongoing in Colorado? - The Colorado facility focuses on quantum technology and low-phase noise oscillator technology, with several senior scientists hired from NIST [22][23] Question: Will margins normalize in the near term? - Management confirmed that they expect margins to normalize as program requirements have been resolved and new contracts are anticipated [39] Question: How does the company view growth opportunities irrespective of political changes? - Management believes that growth in the space sector is largely independent of politics, and defense spending is expected to remain strong due to global security concerns [68][69] Question: Is there potential for Turbo in commercial drones? - Management sees potential for Turbo in both military and commercial applications, but anticipates more immediate opportunities in military [72][73] Question: What is the company's position on international business? - The company has some significant business overseas and is actively pursuing additional opportunities, though export controls present challenges [79][80]

Financial Data and Key Metrics Changes - Comtech reported net sales of $111 million for Q1 2026, a decrease from $130.4 million in the previous quarter, but exceeding the midpoint of revenue guidance [13] - Gross profit for Q1 2026 was $36.8 million, representing a 153.3% increase from $14.5 million in Q1 2025, with a gross profit margin of 33.1% [15] - Operating loss narrowed to $2.8 million in Q1 2026 from a loss of $129.2 million in Q1 2025, with adjusted EBITDA of $9.6 million compared to a loss of $30.8 million in the prior year [16][17] - Operating cash flows improved to $8.1 million in Q1 2026 from negative $21.8 million in Q1 2025, marking the third consecutive quarter of positive cash flow [18] Business Line Data and Key Metrics Changes - The Satellite and Space Communications segment reported a GAAP operating profit of over $3 million in Q1 2026, a significant turnaround from a $119 million operating loss in the same period last year [8] - Illyrium segment achieved adjusted EBITDA of $11.3 million, a slight increase from $11.0 million in the prior year, despite lower net sales in Call Handling Solutions [10] Market Data and Key Metrics Changes - The first quarter's performance was impacted by earlier-than-anticipated orders and net sales, as well as delays due to the recent U.S. government shutdown [14] - Net bookings for Q1 2026 were $101.9 million, resulting in a book-to-bill ratio of 0.92, compared to 1.1 in the prior year [17] Company Strategy and Development Direction - The company is focused on optimizing cash flow and has phased out low-margin products to transition to higher-margin, strategic opportunities [25] - The successful transformation initiatives have positioned Comtech to capitalize on attractive opportunities in each business segment [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's revitalized financial health, which is expected to enhance employee retention, customer trust, and vendor relationships [21] - The company is at an inflection point, with improved margins and attractive growth opportunities ahead [25] Other Important Information - Mary Jane Raymond has joined the board of directors, bringing governance and operational expertise [22] Q&A Session Summary Question: Will the $130 million of new bookings flow to backlog in the current quarter? - A portion will be booked in Q1, but the majority will be booked in Q2 [24] Question: How should investors think about the return to top-line growth? - The focus is on optimizing cash flow, with a deliberate strategy to phase out low-margin business and focus on higher-margin opportunities [25] Question: Any updates on the PIK preferred stock obligation? - No specific comments were made, but the company is exploring various options to improve its capital structure [26]

Financial Data and Key Metrics Changes - Total net revenue for Q3 increased by 7% to $2.6 billion on both a reported and constant currency basis [27] - Comparable sales rose by 2% [27] - Gross profit for Q3 was $1.43 billion, representing 55.6% of net revenue, down from 58.5% in Q3 2024 [29] - Net income for the quarter was $307 million, or $2.59 per diluted share, compared to $2.87 for the third quarter of 2024 [30] Business Line Data and Key Metrics Changes - In the Americas, total revenue declined by 2%, with the U.S. down 3% and Canada down 1% [11] - International revenue increased by 33%, driven by a 46% growth in China Mainland [11][28] - Men's revenue increased by 8%, women's revenue increased by 6%, and accessories and other grew by 12% [28] Market Data and Key Metrics Changes - China Mainland revenue increased by 46%, with comparable sales up by 25% [28] - The rest of the world segment saw revenue grow by 19% on a reported and constant currency basis, with comparable sales increasing by 9% [28] - The company ended the quarter with 796 stores globally, with square footage increasing by 12% [28] Company Strategy and Development Direction - The company is focused on three pillars: product creation, product activation, and enterprise efficiency to drive improvement in the U.S. business [19][26] - Plans to increase new style penetration to 35% in Spring 2026, with a strong pipeline of innovation [20][22] - The company aims to enhance the in-store experience and improve digital engagement to better connect with high-value guests [25] Management's Comments on Operating Environment and Future Outlook - Management noted a slowing trend in demand post-Thanksgiving, which has been factored into Q4 guidance [41] - The company expects revenue growth in Q4 to be below Q3 trends due to calendar shifts [12][33] - Management expressed confidence in the leadership team and the action plan to drive future growth [9][10] Other Important Information - The company has a strong balance sheet with $1 billion in cash and no debt, allowing for continued investment in growth initiatives [27] - The leadership transition is underway, with Calvin McDonald stepping down as CEO and Marty Morfitt serving as Executive Chair [5][9] Q&A Session Summary Question: Can you elaborate on the cadence of demand in the U.S. during Q3? - The quarter progressed as expected, with August being the best month and October the softest, aligning with prior expectations [41] Question: What are the implications of the product assortment changes for operating margins? - There will be puts and takes for operating margins, with a focus on expense savings and efficiencies [42] Question: How did the segments perform this quarter? - The company held share in premium athletic but lost some share in performance apparel due to changing guest behavior [44] Question: How much of the new product pipeline is informed by customer research? - The product innovation process is driven by research focused on unmet needs across various activity categories [47] Question: Can you discuss the performance of the China business? - The company continues to see strong momentum in China, with good performance across all tier cities [60]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $22.6 million, representing a 53% increase compared to the prior year period [6][18] - Gross margin reached 50.6%, up 11 points year over year, marking the first time it surpassed 50% [7][19] - The company expects continued gross margin expansion, aiming for over 70% in the coming years [8][19] Business Line Data and Key Metrics Changes - Approximately 4,700 prescriptions were written for the Assure system in Q2 2026, contributing to revenue growth [6] - Revenue growth was driven by a 54% year-over-year increase in prescriptions, reflecting market share gains and activation of new accounts [18] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is underutilized, with only 14% of the eligible U.S. addressable market currently receiving therapy [9] - The WCD market growth has accelerated to low double digits, indicating a multi-billion-dollar market potential in the coming years [13] Company Strategy and Development Direction - The company is focused on expanding its sales organization to penetrate existing accounts and attract new prescribers [13][14] - The strategy includes enhancing revenue cycle management capabilities and increasing the in-network patient mix, which has improved from approximately 70% to the low 80s [15][19] - The company is investing in clinical evidence generation to influence clinical practice and guidelines [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth, supported by a robust clinical evidence base and an expanding market [17][21] - The company is increasing its fiscal year 2026 revenue guidance to $91 million, reflecting a growth of 52% compared to fiscal year 2025 [21][22] Other Important Information - GAAP operating expenses were $43.2 million in Q2, including non-recurring costs related to professional fees and the recent equity offering [20] - The company reported a GAAP net loss of $32.8 million for the quarter, compared to a loss of $20.6 million in the prior year [21] Q&A Session Summary Question: Guidance for the year and Q3 seasonality - Management discussed the importance of tracking performance on a daily, weekly, and monthly basis, emphasizing a focus on prescription volume growth and in-network mix [25] Question: Use of proceeds from the recent equity offering - The company plans to use the additional capital to strengthen its balance sheet and support key growth drivers [27] Question: Impact of AHA data on market growth - Management noted that the WCD market growth is low double digits, with anecdotal evidence suggesting an increase in clinician awareness and interest following the presentation of clinical data [29] Question: Path for guideline updates - Management clarified that while growth does not rely on guideline changes, they believe the clinical evidence warrants a review [33] Question: Prescription volume sustainability - Management expressed confidence in sustaining prescription growth above 50%, driven by ongoing penetration of existing accounts and the addition of new hospitals [41]

DLH (NasdaqCM:DLHC) Q4 2025 Earnings Call December 11, 2025 10:00 AM ET Company ParticipantsChris Witty - Head of Investor RelationsZach Parker - President and CEOKathryn Johnbull - CFOConference Call ParticipantsJoe Gomes - Senior Research AnalystOperatorGood day and welcome to the DLH Holdings Corp. Fiscal 2025 Fourth Quarter Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. A ...

Financial Data and Key Metrics Changes - The company reported revenue of $81.2 million in Q4 2025, down from $96.4 million in the prior year, primarily due to contract transitions and government efficiency initiatives [14][15] - EBITDA for Q4 was $6.6 million, compared to $10.7 million in the previous year, reflecting lower revenue and pressure on gross margins [15][16] - For the full year, revenue totaled $344.5 million, with EBITDA at $34 million, approximately 10% of revenue, and free cash flow of $23 million [16][17] - The company reduced debt by $10.7 million during the quarter, ending the fiscal year with $131.6 million in debt, a total reduction of $23 million over the year [17][18] Business Line Data and Key Metrics Changes - The revenue decline was attributed to approximately $11 million from small business set-aside conversions, with $7.5 million related to transitioned CMOP locations and $2.9 million from contract unbundling [14][15] - The company has been awarded a sole-source IDIQ contract to continue providing pharmacy and logistics services, with task orders already received [15] Market Data and Key Metrics Changes - The company achieved cybersecurity maturity model level two certification, enhancing its competitive position in the market [7] - The company is optimistic about growth opportunities in its addressable market as it transitions into a leading technology and engineering solutions provider [6][9] Company Strategy and Development Direction - The company is focused on digital transformation, cybersecurity, systems engineering, and scientific research as core capability pillars [9][10] - Investment in proprietary tools like DLH Cyclone, an AI/ML-powered data science engine, is expected to drive organic growth and enhance competitive differentiation [10][12] - The company aims to return to low double-digit organic growth in the future, leveraging its strategic differentiators and top talent [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities despite challenges faced during the fiscal year, emphasizing the importance of diversification and innovation [17][30] - The company anticipates returning to historical growth and EBITDA margins, with new contract awards expected in early 2026 [28][30] Other Important Information - The company has made all mandatory term debt payments through September 30, 2026, a year ahead of schedule [18] - The pipeline of qualified opportunities is strong, exceeding $3 billion, indicating healthy financial growth prospects [31] Q&A Session Summary Question: Status of the Head Start program and potential protest - The company did not participate in the protest regarding the Head Start program transition to small business set-asides, acknowledging the shift in strategy by the government [22] Question: Timeline for remaining CMOP awards - The company is not bidding on remaining CMOP contracts but is supporting a small business partner, with decisions expected in the coming quarter or two [24][25] Question: Expected return to historical growth and EBITDA margins - Management anticipates new business opportunities within the VA and other sectors to positively impact margins, with awards expected in early 2026 [28][30] Question: Current size of the pipeline - The company reported a pipeline exceeding $3 billion, indicating strong growth potential over the next 24 months [31]

Imperial Petroleum (NasdaqCM:IMPP) Q3 2025 Earnings Call December 11, 2025 10:00 AM ET Company ParticipantsHarry Vafias - CEOIfigeneia Sakellari - CFOOperatorGood day, and thank you for standing by. Welcome to the Q3 2025 Imperial Petroleum Results Conference Call and Webcast. At this time, all participants are in a listen-only mode with no question-and-answer session at the end. Please note that today's conference is being recorded. I will now like to turn the conference over to your speaker, Mr. Harry Vaf ...